These findings suggest that TGFβ secreted in the presence of both cancer and immune cells can contribute to resistance to pembrolizumab and atezolizumab and may be related to the high expression of TGFβ in patients who do not respond to anti-PD-(L)1 treatment [7, 8]. The gene discussed is CD274; the disease is cancer.